About Doctor
About Dr. Shuangyou Liu
Dr. Shuangyou Liu is a renowned oncologist and hematologist at Beijing GoBroad Boren Hospital with more than 37 years of clinical and research experience in blood disorders and hematologic malignancies. She is presently Chief Physician and Director of Ward 6 in the General Hematology Department, where she has expertise in leukemia, lymphoma, and other complex hematologic disorders and advanced therapies.
Dr. Liu’s academic background started with a medical degree from Tongji Medical College, Huazhong University of Science and Technology, in 1987. She then pursued a master’s in medicine at the Molecular Medicine Center/Tumor Research Institute of Tongji Hospital, focusing on tumor molecular biology and cell cycle regulation, which she completed in 2005.
She received her PhD in pediatric hematology/oncology in 2008 from the University of Heidelberg, Germany, with a focus on the role of the Notch1 gene in T-lymphocytic leukemia. Her global exposure has also involved serving as a visiting scholar at the Johns Hopkins Bloomberg School of Public Health and conducting research on anemia-associated diseases.
Dr. Liu has led the field of hematology-oncology throughout her career, especially in the use of immunotherapies like CAR-T cell therapy. Her research has greatly helped in understanding and treating relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), including studies on how well humanized CD19-CAR-T cells work. In addition, she has been a principal investigator for several National Natural Science Foundation projects and has written extensively for national and international publications.
Her devotion to patient service and research contribution has made Dr. Liu an eminent expert in hematology and oncology within China and also globally.
Hospital
Specialization
Dr. Shuangyou Liu, a leading hematologist at Beijing GoBroad Boren Hospital, specializes in the diagnosis and treatment of a wide range of hematologic disorders and blood-related cancers. Her core specialties include:
1. Leukemia
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myeloid Leukemia (CML) Dr. Liu is particularly renowned for treating relapsed and refractory forms of leukemia using advanced therapies, including CAR-T cell therapy and targeted molecular treatments.
2. Lymphoma
- Hodgkin’s Lymphoma
- Non-Hodgkin’s Lymphoma She utilizes immunotherapy, chemotherapy, and stem cell transplantation to manage both aggressive and indolent lymphoma types.
3. Myelodysplastic Syndromes (MDS)
Dr. Liu offers personalized treatment plans for MDS, combining hypomethylating agents, immunotherapy, and bone marrow transplant options.
4. Multiple Myeloma
She manages complex cases of multiple myeloma using proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplantation.
5. Aplastic Anemia & Other Bone Marrow Failure Syndromes
Her expertise extends to rare disorders such as aplastic anemia, where she employs immunosuppressive therapy and bone marrow transplantation.
6. CAR-T Cell Therapy
A pioneer in CAR-T therapy, Dr. Liu specializes in developing and administering personalized CAR-T treatments for B-cell malignancies, including B-ALL and certain lymphomas.
7. Hematopoietic Stem Cell Transplantation
She has deep experience in both autologous and allogeneic stem cell transplants, particularly in high-risk or relapsed hematologic malignancies.
Dr. Liu combines cutting-edge research with compassionate care, making her one of China’s foremost specialists in hematology and blood cancer treatment.
Procedures Performed
Dr. Shuangyou Liu is proficient in a wide range of advanced hematologic treatments, especially for blood cancers and bone marrow disorders. Here’s a list of treatments she is highly experienced in:
🔬 Dr. Shuangyou Liu Specializes In Advanced Hematologic Treatments
- Chemotherapy
- For leukemia, lymphoma, myeloma, and other hematologic cancers.
- Includes both induction and consolidation regimens.
- CAR-T Cell Therapy
- Especially for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and lymphomas.
- Proficient in using humanized CD19 CAR-T cells.
- Targeted Therapy
- Includes tyrosine kinase inhibitors (TKIs) for CML.
- FLT3, IDH1/2, and other molecular-targeted agents for AML and MDS.
- Immunotherapy
- Monoclonal antibodies (e.g., Rituximab, Blinatumomab).
- Immune checkpoint inhibitors for certain hematologic malignancies.
- Hematopoietic Stem Cell Transplantation (HSCT)
- Autologous and allogeneic bone marrow transplantation.
- Specialized in transplant protocols for AML, ALL, MDS, and myeloma.
- Supportive Care in Hematology
- Management of neutropenia, anemia, and thrombocytopenia.
- Use of growth factors, transfusions, and antimicrobial prophylaxis.
- Precision Medicine & Molecular Diagnostics
- Personalized treatment planning based on genetic/molecular testing.
- Use of next-generation sequencing (NGS) in diagnosis and prognosis.
- Management of Bone Marrow Failure Syndromes
- Aplastic anemia, myelofibrosis, and related disorders.
- Immunosuppressive therapy (ATG, cyclosporine).
- Pediatric Hematology/Oncology
- With PhD research in pediatric hematologic malignancies.
- Expertise in childhood leukemia and lymphoma treatments.
- Clinical Trials & Translational Research
- Active involvement in clinical studies and new drug development.
- Brings cutting-edge therapies to her patients.
Dr. Liu’s approach combines evidence-based medicine with a strong focus on patient outcomes, making her a leader in modern hematologic cancer care.
Research & Publications
Dr. Shuangyou Liu is a leading hematologist at Beijing GoBroad Boren Hospital, renowned for her pioneering research in chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies. Her work has significantly advanced the treatment landscape for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
One of Dr. Liu’s notable contributions is her involvement in the development and clinical evaluation of Inaticabtagene Autoleucel (Inati-cel; CNCT19), a novel CD19-directed CAR-T therapy. In a phase 2, multicenter study, Inati-cel demonstrated a 3-month overall remission rate of 70.8% among adult patients with r/r B-ALL, leading to its approval as the first CAR-T therapy for this patient population in China.
Dr. Liu has also looked into using combination CAR-T therapies that target both CD19 and CD22 antigens to prevent the loss of these targets and make remission last longer. Her research indicates that dual-targeted CAR-T cell therapy can be effective in inducing remission in patients who have relapsed after allogeneic transplantation.
In addition to clinical trials, Dr. Liu has investigated the use of humanized CD19 CAR-T cells in patients who relapsed after murine CD19 CAR-T therapy, contributing to the understanding of treatment resistance mechanisms.
Her extensive publication record includes studies on the efficacy and safety of CAR-T therapies, biomarkers for predicting treatment outcomes, and strategies to mitigate adverse events such as cytokine release syndrome. Dr. Liu’s research has been published in prestigious journals, reflecting her commitment to advancing hematologic oncology.
Through her innovative research and clinical expertise, Dr. Shuangyou Liu continues to shape the future of CAR-T cell therapy, offering new hope to patients with challenging hematologic cancers.
